Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 203.50 200.00 207.00 203.50 203.50 203.50 282,630 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 365

Amryt Pharma Share Discussion Threads

Showing 4876 to 4894 of 6575 messages
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
DateSubjectAuthorDiscuss
29/8/2019
11:36
mdalos1 29 Aug '19 - 08:20 - 4753 of 4753 0 0 0 Well the huge, time consuming and far too expensive Pack for Shareholders was a challenge BUT ultimately it amounts to just a few basic things: 1) Sell out at an inevitable peak that the whole exercise is nurturing, to profit break even or reduce one's losses 2) Hold in the hope of higher highs as the whole exercise unfolds, particularly if AP101 might come to something - which is itself nothing but a 50:50 gamble at best 3) Hold and ultimately lose out on any benefits 1) or 2) might present as everything eventually comes home to roost I know what I'm going to do, now I'm availed of the fine detail. Won't be seeing you soon enough as I exit somewhere between 1) and 2) this Autumn >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Whatever you do, mdalos, I wish you ATB. The same ATB applies to any existing shareholder whatever they intend to do with their shares. Post EDITED. Nonsense deleted.
papillon
28/8/2019
15:56
I'm hoping that the US$60m placing to be priced at £1.48p (according to yesterday's RNS) means the AMYT share price will be higher that the current share price and closer to that £1.48p when it takes place. Fingers crossed as always! The fact that a non exec, Ray Stafford, has forked out £826k of his cash on buying shares in the initial placing at 90p is, in my opinion, a big vote of confidence in AMYT's future. Either that or he's taken leave of his senses as I can't imagine anyone forking out £826k unless they were either supremely confident, or as mad as a hatter! :-) I'm surprised by the lack of posts today; I'm presuming AMYT is still under the radar of most active PI's. Even Bronxville, on the lse, sounds bullish on AMYT (but not on AP101) citing the Market Cap of Krystal Biotech on Nasdaq as US$750m. Now it appears that Krystal Biotech have not much else in their locker apart from a gene therapy treatment for EB currently being trialled in phase II. AMYT of course have their own gene therapy treatment for EB, namely AP103. It lags a bit behind the competition, but some believe it to be a better bet. We shall see. A US$750m market cap for AMYT on Nasdaq would be nice (current Mkt Cap around £55m), plus AMYT will (hopefully) have other irons in the fire (namely the Aegerion treatments, Mylept and Juxtapid) . Fingers crossed as always.
papillon
28/8/2019
12:10
From yesterday's RNS: "Ray Stafford, Non-Executive Director of the Company, has agreed to subscribe for 918,273 Interim Placing Shares at the Interim Placing Price." >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> At 90p per share that comes to £826,447. Bloody hell, Ray Stafford can't be short of a few bob if he's spending over £800k on AMYT shares!!!!!!!! I'm impressed!! I've joined him this morning, but in a much, much, smaller way: I've spent £400 on a top up! LOL. Well I'm just a poor OAP. I have said recently that my days of gambling on AIM shares is over, but I couldn't resist the temptation after reading how much Ray Stafford was spending! LOL. I might by more before the 20th September cut off date for being eligible to benefit from any future AP101 success.
papillon
27/8/2019
22:18
I would have topped up today, but I didn't know AMYT had relisted until I looked at this bb after the market had closed. Still there is always tomorrow. At the moment I'm very bullish on AMYT. Don't let us poor ignorant sods down, Joe Wiley! Fingers crossed we see a much, much, higher share price in 12 months time. What I liked about AMYT was they made sure they had a revenue stream early on with Lojuxta. Joe Wiley seems like he wants more revenue, lots more, with the Aegerion acquisition. Compare that with PVR & LOGP!!
papillon
27/8/2019
20:53
Very persuasive indeed as I thought that only a couple of weeks ago that chica had a relative who was using amryt products ....and didn't rate them !!! Forgive me if I'm wrong but I can't be bothered checking over old posts ....I hope this board doesn't turn into the likes of PVR And logp :(
richpassi
27/8/2019
18:40
Lara Cutlar - is that the same lady Bronxville met in a pub in Dublin, who convinced him to invest in some Amryt stock? Lara must be a very persuasive lady! Chica1 - you appear to be moving in the same circles as Bronxville. Or perhaps Chica1 = Bronxville. That’s an interesting thought!
diamondstar1
27/8/2019
18:35
The share price closed at 105.5p. That's equivalent to 17.6p pre the 1 for 6 consolidation. A 43.5% increase on the pre suspension price of 12.25p. I'm hopeful of a much higher share price by the time of the placing (and whether the RNS promised 148p will be achieved in practice), Aegerion acquisition and Nasdaq listing are finalised, hopefully in early Q4 2019. Also we have the phase III AP101 trial results to look forward to in early 2020. Of course NOTHING on AIM is ever guaranteed, digadee. FINGERS CROSSED as always! However I'm hopeful on AMYT. I always have been, but that hope has been severely tested over the last 3 years. Fingers crossed AMYT now starts to perform and live up to my expectations.
papillon
27/8/2019
18:24
Lol, yes i know its not complete. My point is you like to give yourself a pat on the back when you get something right. What was the point of your post about the admission. Ohh look at me im so clever, pathetic reallyIts seems you seem to make enemies where ever u go on these boards. Where in my posts have i ramped ???You come across mr know it all and you like to remind folk that you got things right.
digadee
27/8/2019
18:17
I have news for you, digadee. The Aegerion takeover deal HASN'T yet gone through, digadee! I'm hopeful it will (it looks to be a certainty it will), but I never count my chickens until they are hatched. I always accept that nothing in life is ever guaranteed. PS. alphabravo's recent post concerning the American court approval for the takeover made it 99% certain it would happen IMO, digadee. Unlike you (?) I base my opinions on the facts. I also NEVER ramp a share I'm invested in, so I prefer to take a more considered view of the future. I may be bullish on AMYT, but I don't want to be thought of as a RAMPER!
papillon
27/8/2019
17:55
Paps,You also doubted that the deal would go through....
digadee
27/8/2019
17:50
I bought 5000 shares just before close today because I met Lara Cutlar at a recent EB awareness day and she really impressed me.Its really only over .17 pence so I dont think I'm paying too much. Hoping Gene therapy works whether it's be viral or non-viral.
chica1
27/8/2019
17:45
In this post, papillon 5 Aug '19 - 19:44 - 4701 of 4737, I suggested that "Hence it's possible that AMYT could relist as soon the admission document is published in "early August" and before the Aegerion deal is finalised." That's what has happened today, but in late, not early August. I suggested this might happen because this happened with FAST when it acquired AMYT.
papillon
27/8/2019
16:41
The CVR scenario is quite interesting. If i've read it correctly if amryt hits targets for 2022 and 2024.... shareholders will get equivalent of 1 extra share @ £1.28 for every share held.. The CVR Record Date is 20 September 2019.
delta0091
27/8/2019
15:49
Quite right, I wasn't sure so thanks. Looking forward to the broker notes and press.
waterloo01
27/8/2019
15:41
The consolidation was 1 for 6, so 100p now would be 16.66 pre consolidation. Admission document makes interesting reading. There are projections for the acquired business indicating significant net income in 2020 and thereafter. Also some timing for the payments (3 tranches) to old shareholders. Together with the revenue targets for one payment and possible date for approval of AP101. If all works out, shareholders will get current price back in cash plus their share of the upside in a potentially very interesting group. And not that far away. Read the document page 486 in part 3 for projections. Good luck.
sidam
27/8/2019
15:36
Divide the current price by 6
dlm2602
27/8/2019
15:25
Probably being thick here Waterloo but isn't it nearer 18p to 19p?
bermudashorts
27/8/2019
15:14
With the consolidation it's trading at 13p ish (old money) I think
waterloo01
27/8/2019
13:48
The ole pi
barnes4
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 09:52:10